Gene therapy for rare heart disease: Long-Term safety check begins
NCT ID NCT07050160
First seen Nov 12, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This study follows 10 people who already received the experimental gene therapy LX2020 for a genetic heart condition called arrhythmogenic cardiomyopathy. Researchers will monitor them for years to see if the treatment remains safe and continues to work. The goal is to understand long-term risks and benefits, not to offer a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.